Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors
作者:Chao Tian、Zifei Han、Yuanxin Li、Meng Wang、Jiajia Yang、Xiaowei Wang、Zhili Zhang、Junyi Liu
DOI:10.1016/j.ejmech.2018.03.075
日期:2018.5
damaging agents in the treatment of cancer. A novel series of 2,6-disubstituted-9H-purine (3a-p, 5a and 5b), 2,4-disubstituted-thieno[3,2-d]pyrimidine (8a-c) and 2,4-disbustituted-7H-pyrrolo[2,3-d]pyrimidine (11a-c) analogues were designed and synthesized as potent CHK1 inhibitors. Compounds (3a, 3d, 3f and 3j-l) with 9H-purine core displayed more potent inhibition against CHK1. The most potent compound (3l)
Checkpoint激酶1(CHK1)抑制剂可增强脱氧核糖核酸(DNA)破坏剂在治疗癌症中的有效性。一系列新的2,6-二取代的9H-嘌呤(3a - p,5a和5b),2,4-二取代的噻吩并[3,2- d ]嘧啶(8a - c)和2,4-取代的-设计并合成了7H-吡咯并[2,3- d ]嘧啶(11a - c)类似物作为有效的CHK1抑制剂。化合物(3a,3d,3f和3j - 1)具有9H-嘌呤核的化合物显示出对CHK1的更强抑制作用。最有效的化合物(3l)对HT29和Hek293细胞系也表现出较低的抗增殖作用。另外,3l对吉西他滨对HT29细胞的抗增殖活性显示出强大的增强作用(7倍)。细胞周期测定的结果表明3l可以显着影响吉西他滨处理的HT29细胞的细胞周期分布并诱导显着的S期积累。3l的激酶选择性谱显示出对其他激酶的可接受的选择性。这些结果使3l成为CHK1抑制剂的有效先导化合物有待进一步研究。